The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

about

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

Item

http://www.wikidata.org/entity/Q38854234

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The SCOPE of definitive chemor ...... what direction for the future?

@en

type

Item

label

The SCOPE of definitive chemor ...... what direction for the future?

@en

prefLabel

The SCOPE of definitive chemor ...... what direction for the future?

@en

P1476

The SCOPE of definitive chemor ...... what direction for the future?

@en

P2093

Gilles Créhange

http://www.w3.org/2001/XMLSchema#string

Thierry Conroy

http://www.w3.org/2001/XMLSchema#string

P2860

Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer.

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer.

Definitive chemoradiation in patients with inoperable oesophageal carcinoma.

Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study

Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113

Reduced lung dose during radiotherapy for thoracic esophageal carcinoma: VMAT combined with active breathing control for moderate DIBH.

Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer.

P304

1014-1018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/JTD.2016.03.74

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27293806

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

P932

4886021

http://www.w3.org/2001/XMLSchema#string